Found 11 Alzheimer's-disease trials
A listing of Alzheimer's-disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Phase 3
The Study is two research trials aimed at preventing Alzheimer’s disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. AHEAD-3 studies people with intermediate amyloid, while AHEAD-45 studies people with elevated amyloid. Research studies are designed to gain scientific knowledge that may help people in the …
Alzheimers Disease Neuroimaging Initiative 4
The aim of the Alzheimers Disease Neuroimaging Initiative (ADNI) has been to validate biomarkers for Alzheimers disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic …
V-Cog UDSv3 Validation
The purpose of this study is to validate a video-administered cognitive assessment for use by the Alzheimer's Disease Research Centers and other research programs whose activities have been interrupted by the COVID19 pandemic, as well as for use in future initiatives when remote testing will enhance achievement of scientific goals. …
Clinical Core Alzheimer's Disease Core Center (ABC)
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D.. We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data and biological samples, …
START CT1812
The START study is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo for approximately 18 months (72 weeks) in participants diagnosed with early Alzheimers disease.
Aging Brain Cohort Dedicated to Diversity Study TAU PET
Phase 2
To collect Tau PET imaging in cognitively normal older African American (AA) adults in the ABCD2 study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of Alzheimer's disease. Eligible …
Linking Tau PET to Medial Temporal Lobe Subregions with High Resolution MRI
The goal of this research is to collect Tau PET imaging in cognitively normal older adults and patients with Mild Cognitive Impairment (MCI) in the NACC study, to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the mechanisms and distinctions …
Diverse Vascular Contributions to Cognitive Impairment and Dementia (Diverse VCID): White Matter Lesion Etiology of Dementia in Diverse Populations
The purpose of this study is to better understand how blood vessel health impacts your thinking. The study is interested in the brains white matter, which is involved in the movement of messages and impulses throughout the brain. The study is run out of the University of California Davis and …
Healthy volunteers for Neuroinflammatory research study
We are conducting research studies on how immune system cells contribute to inflammatory conditions of the nervous system, such as multiple sclerosis, neuromyelitis optica (NMO), encephalitis, head injury, epilepsy, Parkinson's disease (PD), Alzheimer's disease (AzD), Lou Gherig's disease (amyotrophic lateral sclerosis; ALS) frontotemporal dementia (FTD) and others. This includes investigating …
PI2620
To investigate the sensitivity, specificity, and validity of the tau PET tracer [18F] PI-2620 for measuring toxic tau accumulation in the brain based on how the intensity and anatomical distribution of its uptake differs between cognitively normal adults, amyloid-positive individuals with suspected non-amnestic Alzheimers disease (naAD), and amyloid-negative individuals with …
1 - 10 of 11
- 1
- 2
